Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor
Science Advances · 2023
DOI: 10.1126/sciadv.ade3470 ↗At a glance
Journal article in Science Advances, 2023. Written by Wan Ni Chia and 27 co-authors. Institution: Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore. Major MEDLINE topics: Severe acute respiratory syndrome-related coronavirus, COVID-19. Cited 15 times so far (Crossref); 70 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS.
Abstract (original language)
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern such as Omicron hampered efforts in controlling the ongoing coronavirus disease 2019 pandemic due to their ability to escape neutralizing antibodies induced by vaccination or prior infection, highlighting the need to develop broad-spectrum vaccines and therapeutics. Most human monoclonal antibodies (mAbs) reported to date have not demonstrated true pan-sarbecovirus neutralizing breadth especially against animal sarbecoviruses. Here, we report the isolation and characterization of highly potent mAbs targeting the receptor binding domain (RBD) of huACE2-dependent sarbecovirus from a SARS-CoV survivor vaccinated with BNT162b2. Among the six mAbs identified, one (E7) showed better huACE2-dependent sarbecovirus neutralizing potency and breadth than any other mAbs reported to date. Mutagenesis and cryo–electron microscopy studies indicate that these mAbs have a unique RBD contact footprint and that E7 binds to a quaternary structure–dependent epitope.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
- National Center of Infectious Diseases, Singapore, Singapore.
- Tan Tock Seng Hospital, Singapore, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
- Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Howard Hughes Medical Institute, Seattle, WA, USA.
- Department of Biochemistry, University of Utah, Salt Lake City, UT, USA.
ORCID profiles: Wan Ni Chia, Chee Wah Tan, Aaron Wai Kit Tan, Barnaby Young, Tyler N Starr, Ester Lopez, Guntur Fibriansah, Jennifer Barr, Samuel Cheng, Wee Chee Yap, Thiam-Seng Ng, Wan Rong Sia, Feng Zhu, Shiwei Chen, Jinyan Zhang, Madeline Sheng Si Kwek, Allison J Greaney, Mark Chen, Gough G Au, Prasad N Paradkar, Malik Peiris, Amy W Chung, Jesse D Bloom, David Lye, Sheemei Lok, Lin-Fa Wang
Funding
- NIAID NIH HHS
Cite
APA
Chia, W. N., Tan, C. W., Tan, A. W. K., Young, B., Starr, T. N., Lopez, E., Fibriansah, G., Barr, J., Cheng, S., Yeoh, A. Y., Yap, W. C., Lim, B. L., Ng, T. S., Sia, W. R., Zhu, F., Chen, S., Zhang, J., Kwek, M. S. S., Greaney, A. J., …, & Wang, L. F. (2023). Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor. Science Advances. https://doi.org/10.1126/sciadv.ade3470
Vancouver
Chia WN, Tan CW, Tan AWK, Young B, Starr TN, Lopez E, et al. Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor. Science Advances. 2023. doi:10.1126/sciadv.ade3470
BibTeX
@article{Chia2023,
author = {Chia, Wan Ni and Tan, Chee Wah and Tan, Aaron Wai Kit and Young, Barnaby and Starr, Tyler N and Lopez, Ester and Fibriansah, Guntur and Barr, Jennifer and Cheng, Samuel and Yeoh, Aileen Ying-Yan and Yap, Wee Chee and Lim, Beng Lee and Ng, Thiam-Seng and Sia, Wan Rong and Zhu, Feng and Chen, Shiwei and Zhang, Jinyan and Kwek, Madeline Sheng Si and Greaney, Allison J and Chen, Mark and Au, Gough G and Paradkar, Prasad N and Peiris, Malik and Chung, Amy W and Bloom, Jesse D and Lye, David and Lok, Sheemei and Wang, Lin-Fa},
title = {Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor},
journal = {Science Advances},
year = {2023},
doi = {10.1126/sciadv.ade3470}
}
EUVIMED